Neuraly
Neuraly is a clinical-stage biotechnology company dedicated to developing revolutionary treatments for neurodegenerative diseases such as Parkinson’s and Alzheimer’s. The company focuses on addressing new pathways and leveraging innovative science to create disease-modifying therapies that can change lives. With a strong scientific platform and a talented team, Neuraly aims to be a leader in discovering and developing breakthrough medicines.
Industries
Nr. of Employees
small (1-50)
Neuraly
704 Quince Orchard Rd, Suite 320 Gaithersburg, MD 20878
Patents
Products
BBB-penetrant, long-acting GLP-1R agonist therapeutic (peptide analogue)
A pegylated peptide analogue designed to penetrate the blood–brain barrier and engage GLP-1 receptors on glial cells to reduce neuroinflammation and protect neurons; advanced in clinical development for Parkinson’s disease and Alzheimer’s disease.
Orally active, BBB-penetrant kinase inhibitor small-molecule series
A program of orally active small-molecule kinase inhibitors designed to penetrate the CNS and inhibit glial activation; lead candidates are in IND-enabling evaluation.
Orally active neuroprotective small-molecule program targeting parthanatos cascade
Discovery-stage small molecules that target parthanatos-related pathways to promote neuronal survival; currently in lead optimization and preclinical development.
BBB-penetrant, long-acting GLP-1R agonist therapeutic (peptide analogue)
A pegylated peptide analogue designed to penetrate the blood–brain barrier and engage GLP-1 receptors on glial cells to reduce neuroinflammation and protect neurons; advanced in clinical development for Parkinson’s disease and Alzheimer’s disease.
Orally active, BBB-penetrant kinase inhibitor small-molecule series
A program of orally active small-molecule kinase inhibitors designed to penetrate the CNS and inhibit glial activation; lead candidates are in IND-enabling evaluation.
Orally active neuroprotective small-molecule program targeting parthanatos cascade
Discovery-stage small molecules that target parthanatos-related pathways to promote neuronal survival; currently in lead optimization and preclinical development.
Services
Sponsorship and operational management of clinical trials for neurodegenerative disease programs, including Phase II studies and patient enrollment management.
Development of imaging biomarkers for neuroinflammation and execution of research license and commercialization option agreements.
Development and validation of assays to quantify microglial activation, astrocyte responses, inflammatory cytokines, and neuronal viability.
Collaborative sponsored research with academic institutions to evaluate therapeutic candidates in disease-relevant models and translate findings toward clinical development.
Sponsorship and operational management of clinical trials for neurodegenerative disease programs, including Phase II studies and patient enrollment management.
Development of imaging biomarkers for neuroinflammation and execution of research license and commercialization option agreements.
Development and validation of assays to quantify microglial activation, astrocyte responses, inflammatory cytokines, and neuronal viability.
Collaborative sponsored research with academic institutions to evaluate therapeutic candidates in disease-relevant models and translate findings toward clinical development.
Expertise Areas
- Clinical trial management
- Neurodegenerative therapeutics
- Translational medicine
- Biomarker development and imaging
Key Technologies
- Blood–brain barrier (BBB) penetrant therapeutics
- Long-acting peptide analogues (pegylated formulations)
- GLP-1 receptor agonist modality
- Brain-penetrant kinase inhibitors
News & Updates
Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, announced topline results from the Phase 2 trial with NLY01 in patients with early, untreated Parkinson’s disease (PD).
Neuraly announced the completion of patient enrollment in its Phase 2 study of NLY01 for Parkinson’s disease (PD).
Neuraly announced a publication detailing preclinical data on NLY01's neuroprotective effects in models of Alzheimer’s Disease.
An article discussing the potential impact of the Prism Parkinson’s Research Study on Parkinson’s treatment.
Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, announced topline results from the Phase 2 trial with NLY01 in patients with early, untreated Parkinson’s disease (PD).
Neuraly announced the completion of patient enrollment in its Phase 2 study of NLY01 for Parkinson’s disease (PD).
Neuraly announced a publication detailing preclinical data on NLY01's neuroprotective effects in models of Alzheimer’s Disease.
An article discussing the potential impact of the Prism Parkinson’s Research Study on Parkinson’s treatment.